TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04455672

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: splints
Description: * Scaning of the maxillary and mandibular cast in the centric relation.~* The CAD/ CAM splints will be designed using Exocad s.~* The design will include all maxillary teeth and the occlusal surfaces will be flat and smooth.~* The difference in design between the ARS and the stabilization splint, is that the ARS will have an anterior ramp to allow for posterior disocclusion of posterior teeth, while the stabilization splint will not have such a pronounced anterior ramp.~* Both splints will be printed using Dent2 3D printer and then cured using Dentcure.~* All patient will be asked to wear their spints during sleeping only.~* In each group, patient will be recalled after 1week,2 weeks 1,2and 3monthes then change for the other splint for another 3 months .

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: splints
Description: * Scaning of the maxillary and mandibular cast in the centric relation.~* The CAD/ CAM splints will be designed using Exocad s.~* The design will include all maxillary teeth and the occlusal surfaces will be flat and smooth.~* The difference in design between the ARS and the stabilization splint, is that the ARS will have an anterior ramp to allow for posterior disocclusion of posterior teeth, while the stabilization splint will not have such a pronounced anterior ramp.~* Both splints will be printed using Dent2 3D printer and then cured using Dentcure.~* All patient will be asked to wear their spints during sleeping only.~* In each group, patient will be recalled after 1week,2 weeks 1,2and 3monthes then change for the other splint for another 3 months .
Study: NCT03068338

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Sock
Description: Soft robotic actuator used in a sock design technology to perform plantarflexion and dorsiflexion of the foot about the ankle joint.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent pneumatic compression
Description: Conventional device used by hospitals
Study: NCT02102308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Multicomponent exercise

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Education classes
Study: NCT04339231

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sphenopalatine ganglion block
Description: The block of the sphenopalatine ganglion will be performed bilaterally, using a cotton bud soaked with 1% ropivacaine, placed in the mucosa of the posterior wall of the nasal cavity, through both nostrils.~Once placed in the proper position, the swab will remain for about 20 minutes to absorb the local anesthetic from the mucosa.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sphenopalatine ganglion block
Description: The block of the sphenopalatine ganglion will be performed bilaterally, using a cotton bud soaked with 1% ropivacaine, placed in the mucosa of the posterior wall of the nasal cavity, through both nostrils.~Once placed in the proper position, the swab will remain for about 20 minutes to absorb the local anesthetic from the mucosa.
Study: NCT04104581

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Refined Grain Diet
Description: Subjects will be fed the average American diet except it will be free of whole grains

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Whole Grain Oat Diet
Description: Subjects will be fed the average American diet with addition of a low level of whole grain oats

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Whole Grain Oat Diet
Description: Subjects will be fed the average American diet with addition of a high level of whole grain oats

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Whole Grain Wheat Diet
Description: Subjects will be fed the average American diet with addition of a low level of whole grain wheat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Whole Grain Wheat Diet
Description: Subjects will be fed the average American diet with addition of a high level of whole grain wheat
Study: NCT02535208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restrictive transfusions based on SCOR assessment
Description: RBC transfusions will be given to subjects either when participants' Hgb levels fall below defined values based on respiratory status or, despite not having reached their Hgb trigger threshold, if they manifest symptoms judged by the clinical care team to be consistent with anemia (i.e. apnea, bradycardia, or desaturation episodes) and subsequently have a NIRS evaluation that demonstrates an SCOR \< 0.73.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liberal transfusions
Description: In the liberal group, RBC transfusions will be given to participants when their Hgb level falls below defined values that are based on respiratory support status, as is standard practice.
Study: NCT02206503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: This protocol is a phase II multicenter, open label study designed to determine whether the addition of Cyclophosphamide to Rd (CRd) treatment significantly increases response rates and prolonged the outcome (PFS, OS) in patients who experienced a biochemical relapse, without CRAB under Rd treatment. The treatment period includes: administration of the combination CRd for 9 cycles. In order to assess the efficacy and safety of treatment, patients will attend the study center visits at least every 2 weeks. The response will be assessed after each cycle. During the LTFU period, after development of confirmed PD, all patients are to be followed for survival every 1-3 months via telephone or office visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT01566266

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: 2 capsules of 250mg, 3 times per day during 1 week
Study: NCT01726270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin
Description: 0.4 mg
Study: NCT04059614

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HFNC; COT
Description: HFNC: high-flow nasal cannula therapy COT: conventional oxygen therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HFNC; COT
Description: HFNC: high-flow nasal cannula therapy COT: conventional oxygen therapy
Study: NCT03941054

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure Release
Description: Subjets receive digitopressure during 90 seconds for the treatment of the Myosfascial Trigger Points
Study: NCT02271646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% marcaine 20ml
Description: 3 levels ultrasound guided thoracic paravertebral block at T5-6, T7-8 and T9-10 (total 0.5% marcaine 20ml)
Study: NCT01081769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paliperidone palmitate injection
Description: injection with 150 mg equivalent on Day 1, 100 mg equivalent on Day 8, 75 mg equivalent on Day 38 and flexible dosing with 25, 50, 75, 100 or 150 mg equivalent once monthly thereafter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral antipsychotics
Description: daily treatment according to local label for maximally 24 months
Study: NCT02059655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eye drop solution
Description: Artificial tear drops
Study: NCT03722251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Glucose beverage, control beverage, glucose beverage and active video game playing, control beverage and active video game playing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Glucose beverage, control beverage, glucose beverage and active video game playing, control beverage and active video game playing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Glucose beverage, control beverage, glucose beverage and active video game playing, control beverage and active video game playing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Glucose beverage, control beverage, glucose beverage and active video game playing, control beverage and active video game playing
Study: NCT04013815

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae plane block with ropivacaine
Description: The block is performed immediately before surgery. by an ultrasound guide, with the probe positioned longitudinally, the spinous process of T5 is identified. A peripheral block needle is inserted in the cephalo-caudal direction (caliber 21G and length 10 cm) and 3 ml of physiological solution are injected to confirm the injection site: fascial plane between the erector spinae muscle and the large rhomboid, near the tip of the transverse process of T5. Once the correct position of the needle tip has been confirmed, ropivacaine 0.75% 20 ml is injected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal nerve block with ropivacaine
Description: The intercostal nerve block will be performed by the surgeon at the time of thoracotomy from the 4th to the 8th intercostal space, by injecting 20 ml of 0.75% ropivacaine (4 ml for each space). The injection is performed at about 2-3 cm from the spine.
Study: NCT03881735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enasidenib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo HCT
Study: NCT02438618

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery for Ponto bone anchored hearing aids

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery for Ponto bone anchored hearing aids
Study: NCT03671096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intrastromal TCA Inlay
Description: An intrastromal inlay that will be provided to correct the required hyperopic correction
Study: NCT04386096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mehealth for ADHD software with medication continuity tools
Description: Medication continuity tools integrated within the mehealth for ADHD software will assess factors influencing medication continuity for each adolescent and recommend tools to address relevant factors. Tools include 1) a system to track outcomes and resolve uncertainty about the need for and/or benefit from medicine, 2) a module to address stigma, 3) a module to help manage side effects, and 4) reminders to take medicine and/or request refills.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mehealth for ADHD software with no medication continuity tools
Description: The mehealth for ADHD software has multiple functionalities including 1) online training regarding the American Academy of Pediatrics (AAP) ADHD guidelines; 2) an ADHD workflow wizard that guides pediatricians through the creation of an efficient office workflow to deliver quality ADHD care; 3) online collection of parent- and teacher-report ADHD rating scales for the assessment of ADHD as well as monitoring response to medication treatment; 4) integrated algorithms that automatically score rating scales in real time and provide pediatricians with assessment and treatment reports as well as immediate warnings; 5) an online pediatrician report card; and 6) a Plan-Do-Study-Act wizard that allows pediatricians to select a practice behavior to improve based on their report card and guides them through the creation of small tests of change to improve their office systems.
Study: NCT02836418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATYR1940
Description: Concentrate for solution for infusion
Study: NCT04522518

Intervention type: DEVICE
Intervention: PmP-C App
Description: The key features of PmP-C App include: About Me (entering child's demographic data e.g. age, gender, family members), My participation (answering frequency and involvement of activities), and My goal (selecting 3 important activities they desire to change and identify things that made them easy or hard to do, i.e. participation goals and environmental supports or barriers). The App is to be manipulated adult interviewers but also can be manipulated by the child if they are able to.

Intervention type: DEVICE
Intervention: PmP-C App
Description: The key features of PmP-C App include: About Me (entering child's demographic data e.g. age, gender, family members), My participation (answering frequency and involvement of activities), and My goal (selecting 3 important activities they desire to change and identify things that made them easy or hard to do, i.e. participation goals and environmental supports or barriers). The App is to be manipulated adult interviewers but also can be manipulated by the child if they are able to.
Study: NCT01260350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) tablets administered orally once daily
Study: NCT03964545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: neurofeedback
Description: Patients are instructed to reduce amygdala activation by means of down-regulating the EFP. An auditory feedback interface is used with the instruction to down-regulate volume of a jingle, reflecting intensity of EFP.
Study: NCT03800745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colace 100Mg Capsule
Description: Prescribed to Arm B
Study: NCT02518048

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 90100 Aerosol foam
Study: NCT03800745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miralax
Description: Prescribed to Arm C
Study: NCT02518048

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betesil® 2.25 mg
Study: NCT02858583

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CC+SI
Description: chest compression will be delivered during sustained inflation (CC+SI). The duration of each sustain inflation is 20sec. After 20sec a pause of 1sec id done before the next sustained inflation is delivered for another 20sec. Chest compressions are given continuously. This approach is continued until return of spontaneous circulation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3:1 C:V
Description: During 3:1 C:V. 3 chest compressions are given, then stopped and then 1 inflation is given. This approach is continued until return of spontaneous circulation.
Study: NCT03347305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: automated DP
Description: Energy expenditure measurement

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calorimetric chamber
Description: The main objective is to compare DE and its variations according to the conditions (rest, sleep, meals, physical activity) in patients treated with automated DP compared to controls, in a calorimetric chamber
Study: NCT02148796

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Broncho-Vaxom (BV)
Description: Active Ingredient: Lyophilised bacterial extract; Chemical Name: OM-85 BV; Strength: 3.5 mg; Excipients: bacterial extract, propyl gallate, sodium glutamate, mannitol, pregelatinised starch, magnesium stearate; Appearance: Blue and white capsule; Dosage Form: 3.5 mg capsule; Manufacturer: OM Pharma, Switzerland (OM stands for Omnia Medicamenta) Storage: Store in the original package

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo capsule will be used that will be indistinguishable from the active study drug.
Study: NCT00408642

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced adherence support
Description: The enhanced adherence support intervention consists of 5 one-on-one, Information-Motivation-Behavioral Skills (IMB) theory-based counseling sessions, as well as a problem-solving card which summarizes key messages and strategies. The counseling sessions are given at key points post-initiation of therapy: at baseline, 2 weeks, 2 months, 3 months, and 6 months. Three brief weekly ART planning sessions are conducted post-initiation of therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard adherence support
Description: The control arm receives the standard of care adherence support which consists of three group counseling adherence sessions conducted prior to initiation of therapy.
Study: NCT06578442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Field Treatment
Description: Magnetic Field Treatment was applied to the participants for 30 minutes a day, twice a week for 8 weeks, using an electromagnetic field therapy device, in a supine position, by placing circular magnetotherapy electrodes in the abdominal area, at 25 Hz and 30 Gauss power.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constipation Coping Training
Description: The control group was given constipation coping training and asked to perform the taught methods every day for 8 weeks. Whether the individuals applied the methods was checked every day via telerehabilitation.
Study: NCT00777270

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: repair of episiotomy or second degree tears
Description: continuous suture technique with continuous non-locking suture in the vagina, perineum and subcutaneous tissue.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: repair of episiotomy or second degree tears
Description: interrupted technique with continuous locking suture of the vagina, interrupted sutures in the perineum muscle and interrupted transcutaneous suture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: repair of episiotomy or second degree tears
Description: interrupted technique with continuous locking suture of the vagina, interrupted sutures in the perineum muscle and interrupted transcutaneous suture
Study: NCT03525275

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Battlefield Acupuncture
Description: Battlefield Acupuncture uses ASP semi-permanent needles inserted into their ears for pain attenuation in 5 known points. Both groups receive their respective post-surgical rehabilitation protocols

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post-surgical shoulder protocol
Description: Surgery specific post-surgical physical therapy protocol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Post-surgical shoulder protocol
Description: Surgery specific post-surgical physical therapy protocol
Study: NCT02941211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aqueduct -100
Study: NCT02757833

Intervention type: OTHER
Group type: OTHER
Intervention: A 3 Tesla MRI scanner (Siemens, Erlangen Germany), will be used to measure levels of GSH in the brain.
Description: Using the MEGA-PRESS pulse sequence, high resolution T1-weighted sagittal anatomic images covering the brain using an inversion-prepared MP-RAGE pulse sequence to produce high grey/white matter contrast will be acquired. These will be used to localize the spectroscopy voxel in the vmPFC. Magnetic field homogeneity will be optimized in the voxel using an automated map shimming procedure. MEGA-PRESS spectra will be acquired to detect the glutathione cysteinyl ß-CH2 peak at 2.95 ppm with the editing pulse set at the j-coupled a-CH resonance at 4.95 ppm. A reference unsuppressed water spectrum will be acquired for absolute quantification. Metabolite spectra will be fitted in the time domain using a Levenberg-Marquardt least squares minimization routine. The contribution of each metabolite to the in-vivo spectrum can be scaled to the water signal intensity from within the voxel of interest to obtain an absolute measurement of metabolite concentration.

Intervention type: OTHER
Group type: OTHER
Intervention: A 3 Tesla MRI scanner (Siemens, Erlangen Germany), will be used to measure levels of GSH in the brain.
Description: Using the MEGA-PRESS pulse sequence, high resolution T1-weighted sagittal anatomic images covering the brain using an inversion-prepared MP-RAGE pulse sequence to produce high grey/white matter contrast will be acquired. These will be used to localize the spectroscopy voxel in the vmPFC. Magnetic field homogeneity will be optimized in the voxel using an automated map shimming procedure. MEGA-PRESS spectra will be acquired to detect the glutathione cysteinyl ß-CH2 peak at 2.95 ppm with the editing pulse set at the j-coupled a-CH resonance at 4.95 ppm. A reference unsuppressed water spectrum will be acquired for absolute quantification. Metabolite spectra will be fitted in the time domain using a Levenberg-Marquardt least squares minimization routine. The contribution of each metabolite to the in-vivo spectrum can be scaled to the water signal intensity from within the voxel of interest to obtain an absolute measurement of metabolite concentration.
Study: NCT04039568

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Enhancement Program (HEP)
Description: This is the active control group of the study, where participants will be educated on health promotion, healthy diet, music, and exercise, but do not learn breathing techniques, or meditation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sahaj Samadhi Meditation (SSM)
Description: This is the experimental arm of the study, where participants will be trained in a form of meditation that may improve depressive symptoms.
Study: NCT01636193

Intervention type: BIOLOGICAL
Intervention: Oral Rotarix®
Description: 2 doses administered orally.

Intervention type: OTHER
Intervention: Data collection
Description: Safety data will be collected through the check of health observation diary and interview of vaccinee's parent.
Study: NCT01082705

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: artemether-lumefantrine
Description: administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine at a dosage of: 1 tablet for patients weighing 5-14 kg, 2 tablets for patients weighing 15-24 kg, 3 tablets for patients weighing 25-34 kg, 4 tablets for patients weighing 35 kg or more

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Description: once daily for 3 days as tablets containing 40 mg of dihydroartemisinin and 320 mg of piperaquine at a total dosage of 6.4 mg/kg of dihydroartemisinin and 51.2 mg/kg of piperaquine divided equally between the three days